Skip to content

Erasca, Inc. ERAS Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.56B-57.1%
Eli Lilly logo
Eli LillyLLY
-$3.47B-351%
Pfizer logo
PfizerPFE
-$2.86B+45.4%
Amgen logo
AmgenAMGN
$1.44B+135%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$238.74M+27,216%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$79.85M+3,992,200%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s financing cash flow?
Erasca, Inc. (ERAS) reported financing cash flow of $244.66M in Q1 2026.
How has Erasca, Inc.'s financing cash flow changed year-over-year?
Erasca, Inc.'s financing cash flow increased by 741306.1% year-over-year, from $33K to $244.66M.
What is the long-term trend for Erasca, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Erasca, Inc.'s financing cash flow has grown at a -77.7% compound annual growth rate (CAGR), from $439.4M to $1.1M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.